Trials / Active Not Recruiting
Active Not RecruitingNCT05918692
A Phase 1 Study of BMF-500 in Adults With Acute Leukemia
A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study of BMF-500, an Oral Covalent FLT3 Inhibitor, in Adults With Acute Leukemia
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Biomea Fusion Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.
Detailed description
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adult patients with acute myeloid leukemia (AML), who may or may not be on Antifungals.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMF-500 | Investigational Product |
Timeline
- Start date
- 2023-07-26
- Primary completion
- 2026-04-01
- Completion
- 2026-04-01
- First posted
- 2023-06-26
- Last updated
- 2026-02-23
Locations
14 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05918692. Inclusion in this directory is not an endorsement.